Home › Companies › NKTR

Nektar Therapeutics

NKTR Lead: Phase 2 1 Biotech Distilled article ↓

Dermatology Immunology Metabolic Oncology Protein

Most recent annual filing: 2026-03-13

Pipeline (11 active programs)

rezpegaldesleukin

Protein Target: IL-2 receptor complex

Atopic Dermatitis Phase 2 subcutaneous
Alopecia Areata Phase 2 subcutaneous
Type 1 Diabetes Phase 2 subcutaneous TrialNet
Cutaneous Lupus Erythematosus Phase 1 subcutaneous

NKTR-0165

Protein Target: TNFR2

Undisclosed indication Preclinical Biolojic Design, Ltd.

NKTR-0166

Protein Target: TNFR2

Undisclosed indication Preclinical

NKTR-255

Protein Target: IL-15

Large B-Cell Lymphoma Phase 2 Fred Hutchinson Cancer Center
Urothelial Carcinoma Phase 2 Merck KGaA
Non-Small Cell Lung Cancer Phase 2

NKTR-422

Protein Target: CSF1

Undisclosed indication Preclinical

NKTR-288

Protein Target: IFN-γ

Undisclosed indication Preclinical

Biotech Distilled coverage (1)

2026-06-06 Nektar Therapeutics (NKTR) — Scientific Deep Dive for Rezpegaldesleukin and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.